Cover Image
市場調查報告書

類鐸受體3:開發中產品分析

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 366667
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
類鐸受體3:開發中產品分析 Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 69 Pages
簡介

本報告提供以類鐸受體3為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

類鐸受體3 (CD283 or TLR3) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Biomics Biotechnologies Co., Ltd.
  • Hemispherx Biopharma, Inc.
  • Idera Pharmaceuticals, Inc.
  • Innate Pharma S.A.
  • Johnson & Johnson
  • MultiCell Technologies, Inc.
  • Oncovir, Inc.
  • Tollys S.A.S

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0809TDB

Summary

Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll Like Receptor 3 - Pipeline Review, H1 2017, outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response. The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 3, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Respiratory, Immunology, Gastrointestinal, Cardiovascular, Central Nervous System, Dermatology, Metabolic Disorders and Other Diseases which include indications Breast Cancer, Asthma, Autoimmune Disorders, Chronic Inflammation, Melanoma, Ovarian Cancer, Renal Cell Carcinoma, Acute Inflammation, Atherosclerosis, Bladder Cancer, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), Chronic Obstructive Pulmonary Disease (COPD), Colitis, Colon Cancer, Cutaneous T-Cell Lymphoma, Diabetic Foot Ulcers, Ebolavirus Infections (Ebola Hemorrhagic Fever), Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammation, Inflammatory Bowel Disease, Influenza A Virus, H5N1 Subtype Infections, Injury, Liver Cancer, Lymphoma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pandemic Influenza, Peritoneal Cancer, Pressure Ulcers, Prostate Cancer, Pulmonary Inflammation, Rhinovirus Infections, Sarcomas, Severe Acute Respiratory Syndrome (SARS), Venous Leg Ulcers (Crural ulcer), West Nile Virus Infections, Wounds and Zika Virus Infections.

Furthermore, this report also reviewsalso reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3)
  • The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Toll Like Receptor 3 (CD283 or TLR3) - Overview
    • Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development
    • Hemispherx Biopharma Inc
    • Innate Pharma SA
    • Johnson & Johnson
    • MultiCell Technologies Inc
    • Oncovir Inc
    • RMB-Research GmbH
  • Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles
    • Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CNTO-3157 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CU-CPT4a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Activate TLR3 for Atherosclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IPH-33 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MCT-465 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotide to Agonize TLR3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PEP-0202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Poly-ICLC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PrEP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rintatolimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Statmicoll - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Toll Like Receptor 3 (CD283 or TLR3) - Dormant Products
  • Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products
  • Toll Like Receptor 3 (CD283 or TLR3) - Product Development Milestones
    • Featured News & Press Releases
      • May 31, 2017: Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology
      • May 15, 2017: Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2017
      • Mar 06, 2017: Hemispherx Biopharma Meets Ampligen Sales Milestone in the 1st Quarter of 2017
      • Feb 09, 2017: hVIVO announces data from two Phase IIa clinical studies to further profile PrEP Biopharm's PrEP-001 as a potential prophylactic against the common cold
      • Jan 26, 2017: Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen) for Sale to Early Access Program in Europe
      • Jan 11, 2017: Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients
      • Oct 31, 2016: Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen Phase III Trial in Patients with CFS/ME
      • Oct 19, 2016: Hemispherx Biopharma Announces Completion of Ampligen Manufacturing Technology Transfer Milestone
      • Aug 29, 2016: Hemispherx Biopharma to Present Data on the Activity of Ampligen Against Cancer at CHI's 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA
      • Aug 23, 2016: Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
      • Jul 27, 2016: Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen
      • Jul 25, 2016: Hemispherx Announces First Shipment of Rintatolimod (Ampligen) to Early Access Program in Europe
      • Jun 14, 2016: hVIVO - Favourable results for PrEP Biopharms Flu Study
      • Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, "Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)" in Expert Review of Clinical Pharmacology
      • Jun 06, 2016: Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indications, H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Hemispherx Biopharma Inc, H1 2017
  • Pipeline by Innate Pharma SA, H1 2017
  • Pipeline by Johnson & Johnson, H1 2017
  • Pipeline by MultiCell Technologies Inc, H1 2017
  • Pipeline by Oncovir Inc, H1 2017
  • Pipeline by RMB-Research GmbH, H1 2017
  • Dormant Products, H1 2017
  • Dormant Products, H1 2017 (Contd..1), H1 2017
  • Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top